Eloralintide: Eli Lilly's Amylin Drug That Just Beat Cagrilintide and Petrelintide in Phase 2

Añadido: 2026-05-27

[00:00:00]If you've watched my videos on cagrilintide and petrelintide, you know there's a three-player amylin race in obesity drug development. The third player just leapfrogged both of them in phase two.

[00:00:11]Here's the documented story.

[00:00:13]What a lorlatinide is.

[00:00:16]A lorlatinide is Eli Lilly's selective amylin receptor agonist.

[00:00:20]It's a once-weekly subcutaneous injection. Same dosing format as cagrilintide and petrelintide.

[00:00:27]Like the others, it mimics amylin, the pancreatic hormone your beta cells cosecrete with insulin.

[00:00:33]It activates amylin receptors to suppress appetite, slow gastric emptying, and signal satiety through brainstem pathways.

[00:00:42]Mechanistically distinct from GLP-1, GIP, and glucagon.

[00:00:47]But the phase two results genuinely changed the competitive picture.

[00:00:51]On November 6th, 2025, Lilly announced phase two results at Obesity Week and simultaneously published in The Lancet.

[00:00:59]263 adults with obesity or overweight plus at least one weight-related comorbidity, no type two diabetes, 48 weeks of treatment.

[00:01:09]The headline number, 20.1% mean weight loss at the 9-mg dose.

[00:01:15]That's about 21 kg, 47 lb.

[00:01:18]Placebo was 0.4%.

[00:01:21]For reference, petrelintide supreme one showed 10.7% at 42 weeks.

[00:01:28]Cagrilintide monotherapy phase two showed 10.8% at 26 weeks.

[00:01:34]A lorlatinide approximately doubled the standalone amylin weight loss numbers.

[00:01:39]Plus tolerability.

[00:01:41]80% of the 9-mg group improved by at least one BMI category.

[00:01:46]The most common adverse events were mild to moderate gastrointestinal symptoms, similar to placebo at lower doses.

[00:01:54]That combination, high efficacy and favorable tolerability is the genuinely distinctive thing about a loralintide.

[00:02:02]The phase three program.

[00:02:04]The enlighten one phase three trial started in 2026 and is expected to continue through 2028.

[00:02:11]Lilly is also studying a loralintide in combination with tirzepatide, leveraging their already approved GLP-1/GIP dual agonist as the combination partner.

[00:02:22]The amylin race just got more interesting.

[00:02:25]Worth watching what comes next.